Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMFI46A)

Drug Name
Argatroban Drug Info
Synonyms
Acova; Argatrobanum; MMTQAP; MPQA; Novastan; Argatrobanum [Latin]; MITSUBISHI INHIBITOR; MCI 9038; MD 805; MD805; Argatroban (anhydrous); Argatroban [INN:JAN]; GN-1600; MCI-9038; MD-805; MQI-ARG-MCP; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3R)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3S)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-4-Methyl-1-((S)-N(sup 2)-(((RS)-1,2,3,4-tetrahydro-3-methyl-8-quinolyl)sulfonyl)arginyl)pipecolic acid; (2R,4R)-4-Methyl-1[Nalpha-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl)]-2-piperadinecarboxylic acid; (2r,4r)-4-methyl-1-[n2-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-l-arginyl]-2-piperidinecarboxylic acid; 21R-Argatroban; 4-methyl-1-(N(2)-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl)-2-piperidinecarboxylic acid
Therapeutic ClassAnticoagulants
Cross-matching ID
PubChem CID
92722
ChEBI ID
CHEMBL1166
CAS Number
CAS 74863-84-6
TTD Drug ID
D07UWV
INTEDE Drug ID
DR0132

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
ECM-receptor interaction 1.93 0.00e+0 80/88 (90.91%) COL4A2;AGRN;ITGA4;...
Fat digestion and absorption -1.59 4.67e-2 35/43 (81.4%) GOT2;ACAT2;PLPP1;...
Parkinson disease -1.62 3.30e-2 176/249 (70.68%) COX7A2;NDUFB3;HSPA5;...
Pyruvate metabolism -1.62 3.39e-2 41/47 (87.23%) LDHC;DLAT;ALDH2;...
Influenza A -1.62 3.45e-2 156/172 (90.7%) TNFRSF10B;IL18;BAK1;...
Caffeine metabolism -1.64 2.95e-2 5/6 (83.33%) CYP2A6;XDH;CYP1A2;...
Cytosolic DNA-sensing pathway -1.67 2.26e-2 52/63 (82.54%) NFKBIA;POLR3G;IL18;...
Arachidonic acid metabolism -1.69 2.00e-2 48/61 (78.69%) GPX2;AKR1C3;PTGES;...
Propanoate metabolism -1.71 1.85e-2 30/34 (88.24%) EHHADH;LDHC;PCCA;...
Nitrogen metabolism -1.71 1.86e-2 16/17 (94.12%) CA4;CPS1;GLUD1;...
African trypanosomiasis -1.72 1.87e-2 32/37 (86.49%) IL18;KNG1;F2RL1;...
Peroxisome -1.74 1.61e-2 72/82 (87.8%) PEX26;PRDX1;HAO2;...
Valine, leucine and isoleucine degradation -1.74 1.65e-2 42/48 (87.5%) ALDH1B1;PCCB;ACADSB;...
Tyrosine metabolism -1.75 1.45e-2 30/36 (83.33%) TYR;GSTZ1;TAT;...
Pentose and glucuronate interconversions -1.76 1.49e-2 17/34 (50%) GUSB;UGP2;UGT2A3;...
Renin-angiotensin system -1.77 1.31e-2 20/23 (86.96%) CTSA;ENPEP;AGT;...
Proximal tubule bicarbonate reclamation -1.82 6.96e-3 21/23 (91.3%) GLS2;PCK2;ATP1A2;...
alpha-Linolenic acid metabolism -1.83 6.84e-3 17/25 (68%) PLAAT3;ACOX1;PLA2G12A;...
Alanine, aspartate and glutamate metabolism -1.91 6.70e-4 27/37 (72.97%) GFPT2;GOT2;ASPA;...
Steroid hormone biosynthesis -1.98 7.26e-4 43/61 (70.49%) AKR1C4;CYP1A1;CYP21A2;...
Complement and coagulation cascades -1.99 7.91e-4 76/85 (89.41%) MBL2;PLAU;FGA;...
Arginine biosynthesis -2.01 8.71e-4 17/22 (77.27%) GOT2;ASL;CPS1;...
Metabolism of xenobiotics by cytochrome P450 -2.02 9.67e-4 49/77 (63.64%) SULT2A1;CYP1A1;GSTO1;...
Proteasome -2.03 1.09e-3 44/46 (95.65%) PSMA5;PSMD4;PSMD1;...
Drug metabolism -2.07 1.24e-3 78/151 (51.66%) CYP2A6;DPYS;GUSB;...
Porphyrin and chlorophyll metabolism -2.10 0.00e+0 23/43 (53.49%) GUSB;BLVRA;FECH;...
Retinol metabolism -2.15 0.00e+0 41/68 (60.29%) ALDH1A3;CYP2B6;RDH5;...
Fatty acid degradation -2.17 0.00e+0 40/43 (93.02%) ACADSB;ACSBG1;ACAA1;...
Glycine, serine and threonine metabolism -2.22 0.00e+0 31/40 (77.5%) CBS;GRHPR;ALAS1;...
Linoleic acid metabolism -2.22 0.00e+0 21/29 (72.41%) PLAAT3;CYP1A2;PLA2G12A;...
Mineral absorption -2.45 0.00e+0 48/60 (80%) ATP1A2;SLC26A3;SLC30A1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 3.33uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 6.66uM 72H
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 3.33uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 3.33uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 3.33uM - 10uM 24H
Urinary bladder
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 3.33uM - 10uM 24H